glp-1 receptor agonist type 1 diabetes randomized trial Enrollment of Females in Trials for Glucagon-Like Peptide Agonists: A Systematic Review Comparative effectiveness of GLP-1 receptor

The global prevalence of 537 million affected in the age group of 2079 years in 2021 will rise to 783 million in 2045, with the lowest increase in incidence in Europe (13%) and the highest in the African countries south of the Sahara (134%) (1)

Why the new trial matters The TAG-MS trial, reported by Multiple Sclerosis News Today on May 7, is structured to address the mechanism question directly

People with sleeve gastrectomy and those who regained more weight post-surgery were more likely to use GLP-1 drugs.

GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives

Chronotherapeutic effects of Allu on hyperphagic obesity Impaired diurnal feeding rhythm is implicated in development of obesity, diabetes, and metabolic syndrome in humans and rodents 3,4,28